What Caused the Intranasal Mass in This Woman's Nose?
Oct 18, 2018
A 52-year-old woman presents with nasal congestion and an intranasal mass. What is your diagnosis?
Recent Content
Monitoring Residual Disease in Colon Cancer
Oct 18, 2018
Dr. Luis Diaz spoke with Cancer Network about monitoring for residual disease in colon cancer ahead of his presentation at ESMO 2018.
Recognizing the Side Effects of Newly Approved CLL Therapies
Oct 18, 2018
Dr. Ian Flinn spoke with Cancer Network about incorporating the newest approved therapies for the management of CLL.
Do Some Prostate Cancer Therapies Raise Patients’ Risks for Bladder Cancer?
Oct 18, 2018
Treatment for prostate cancer with external beam radiotherapy was found to be associated with an increased risk for development of bladder cancer when compared with radical prostatectomy.
The Black Box in Cancer: Dealing With the Unthinkable
Oct 18, 2018
In his latest blog, Craig Hildreth explores the terror of the black box warning and how the fear of toxicities affects his patients—and his staff.
Herb-Drug Interactions in Cancer Care
Oct 17, 2018
In this article, we describe the mechanisms via which interactions between herbs and prescription drugs may occur, and highlight four popular herbs and a medicinal mushroom commonly used by cancer patients, along with reports of their interactions with standard drugs.
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer
Oct 17, 2018
An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?
Gene Expression Assays in Early-Stage Breast Cancer
Oct 17, 2018
Dr. Sparano discusses the implications of TAILORx, the first trial to use Oncotype DX in clinical decision making.
When to Order an MRI in the Initial Evaluation and Management of Prostate Cancer
Oct 17, 2018
This article summarizes the current role of multiparametric MRI in the diagnosis, risk assessment, and treatment of prostate cancer.
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue
Oct 17, 2018
Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.
